FIME Show - Florida International Medical Exhibition’s Post

Brilliant summary of the research we do in Mankin/Vázquez-Laslop lab, where we study how naturally-derived antimicrobial peptides from insects act to inhibit protein synthesis in bacteria. This research crucial for developing treatments against antibiotic-resistant pathogenic bacteria.

𝐂𝐑𝐓 (𝐂𝐥𝐨𝐭 𝐑𝐞𝐭𝐫𝐢𝐞𝐯𝐞𝐫 𝐓𝐞𝐬𝐭𝐢𝐧𝐠) 𝐌𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞 We are thrilled to announce a significant milestone in our journey towards advancing medical device testing: Safety Evaluation of Clot Retrieval Devices in the porcine model with outstanding results!   𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: ✅ 𝐒𝐚𝐟𝐞𝐭𝐲 𝐚𝐧𝐝 𝐄𝐟𝐟𝐢𝐜𝐚𝐜𝐲: The device demonstrated exceptional safety and efficacy in removing clots, paving the way for improved outcomes of patient. ✅ 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐃𝐞𝐬𝐢𝐠𝐧: Our team has worked tirelessly to develop a large animal model with modern Cathlab, scientific acumen and skills that passed all the international QMS standards.  ✅ 𝐏𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐅𝐮𝐭𝐮𝐫𝐞: These positive results bring us one step closer to clinical trials of the device that ultimately, provide a life-saving solution for patients suffering from stroke and other clot-related conditions. A huge thanks to our dedicated #MRIDA team and partners for their hard work and commitment. Together, we are making strides in medical innovation and improving lives. #MIRDA is the Medical Devices Testing and Training Division of Palamur Biosciences Pvt Ltd Biotechnology Industry Research Assistance Council (BIRAC) #MedicalDeviceTesting #ClotRetrieverTesting #PorcineModel #Innovation #StrokeTreatment #ClotRelatedConditions #ClinicalTrials #Cathlab #LargeAnimalModel #MRIDA #MedicalInnovation #SavingLives #Healthcare #Biotechnology #Palamurbiosciences #Palamurbio

🎯🚀 𝐓𝐡𝐞 𝐀𝐭𝐡𝐥𝐞𝐭𝐢𝐜𝐢𝐬𝐦 𝐨𝐟 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞𝐬 𝐢𝐧 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 Ever considered drug discovery as a high-stakes game of molecular darts? You've got a plethora of compounds lined up, aiming for the bullseye - a crucial protein target. Landing a hit? That's just round one. Imagine your winning compound as an elite marathon runner. It's got a significant race ahead - getting absorbed, reaching the right spots, metabolizing without a hitch, and exiting gracefully post-job. Welcome to the ADME Olympics - your casual drug development project. This is where our compound needs a top-notch coach, and that's where ADME profiling comes into play. It spots the snags in our compound's fitness - poor absorption, too-fast metabolism - and helps us tweak the training regimen. Without this, we're shooting in the dark. Cue the computational tools, our digital coach with the processing power of a supercomputer. These tools sift through our contenders, guiding us on which molecules to test and which assays to run first. It's a meticulous integration, not just a casual add-on, ensuring our drug discovery race is sleek and strategic. Getting ADME predictions right early on isn't just playing it safe; it's the bare minimum nowadays. It increases our success odds, carves paths for novel treatments, and differentiates a dust-gathering compound from a life-altering medication. So, here's the goal - let's not just aim to hit the target. Let's craft treatments with the endurance to make a real-world impact. What's your strategy for navigating the complex molecular maze? #MedicinalChemistry #DrugDiscovery #PharmaDevelopment #ADME

Lipum to participate in the following upcoming events and meetings: NLSDays | 18-19 September | Malmö BioEurope | 4-6 November | Stockholm Redeye Autoinflammatory day | 20 November | Stockholm BioStockSummit | 20-21 November| Lund "These meetings provide a good opportunity for us to present and discuss our progress and results from our first clinical phase 1 study, to share our ongoing plans as well as presenting key milestones and triggers with investors and partners" says CEO Ola Sandborgh. #lipum #investorrelations #lifescience

Today we'll talk about a rare but groundbreaking technology that Neoteryx has managed to study, develop and spread! The microsampling. Microsampling refers to a method of collecting small volumes of biological samples, typically blood, for various analytical purposes. The "Mitra" device is one such tool designed for microsampling. It utilizes volumetric absorptive microsampling (VAMS) technology, allowing precise and controlled collection of a fixed volume of blood from a fingerstick or another minimally invasive method. The Mitra device consists of an absorbent tip that holds a specific and consistent amount of blood. This sample is then dried and stored on the device for later analysis. Microsampling, particularly with the Mitra device, offers several advantages: - Minimal Invasiveness: Microsampling requires only a small amount of blood, making it a less invasive alternative to traditional venipuncture methods. - Ease of Collection: The simplicity of sample collection, often through a simple fingerstick, reduces the need for skilled personnel and provides a more convenient experience for both healthcare professionals and patients. - Reduced Sample Volume: Microsampling significantly reduces the volume of biological samples needed for analysis, conserving resources and minimizing the impact on individuals. - Improved Patient Compliance: The less invasive nature of microsampling can enhance patient comfort and increase compliance with sample collection protocols, especially in longitudinal or frequent sampling scenarios. - Stability and Storage: Dried blood samples on the Mitra device are stable and can be stored for an extended period, allowing flexibility in transportation and analysis. - Remote Sampling: Microsampling facilitates remote sampling, enabling individuals to collect samples at home, which is particularly beneficial for decentralized clinical trials and remote patient monitoring. - Cost-Efficiency: The reduced need for specialized personnel, smaller sample volumes, and simplified logistics contribute to cost savings in terms of both time and resources. Microsampling, with devices like Mitra, has emerged as a valuable technology in various fields, including clinical research, pharmacokinetic studies, and therapeutic drug monitoring, offering a more patient-friendly and efficient approach to sample collection and analysis. #microsampling #laboratory #bloodtest #test #diagnostic #clinicaldiagnostics #trajan #neoteryx #samples #sample #innovation #innovativemeditech #UAE #KSA #Jordan #GCC

Looking forward to AOPA and sharing MyoPro research and clinical findings. Find me in the program and lets compare notes. #aopa2024 #orthotics #prosthetics #weareoandp #myomo #myopro #medDevice

🌍 Exciting Times at the European #Workshop for Drug Design 2024! Dompé as part of the Ligate Project is thrilled to share highlights from the #EWDD24 held in the beautiful city of Siena, Italy. The conference was a remarkable success, providing a platform for pioneering discussions and collaborative learning within the scientific community. Dr. Akash Deep Biswas (PhD) presented groundbreaking work. We demonstrated the execution of over 16,442 molecular dynamics (MD) simulations, each lasting 250 nanoseconds, and binding free energy (BFE) calculations as part of the BAP Workflow. These simulations provide detailed insights into the behavior of molecules over time, aiding in the design of more effective drugs. Additionally, we completed over 8 million MD simulations, each 100 picoseconds long, and corresponding BFE calculations for the PS Workflow. These shorter simulations still offer valuable data on molecular interactions and are crucial for the rapid evaluation of potential drug candidates. These efforts underline the Ligate Project #commitment to advancing computational drug design, and it was inspiring to see such significant recognition and appreciation from our peers. A heartfelt thank you to the organizers and all participants for making this event so impactful. We are excited to leverage these insights to drive further innovation in drug discovery and development. #EWDD24 #DrugDesign #MDsimulations #BFEcalculations #LIGATE #Innovation #ScientificResearch #Networking #ML #AI #CADD #insilico #simulation

I recently attended the #EWDD24 European #Workshop in #Drug #Design 2024 in #Siena on behalf of the #Exscalate group of Dompé. We perceive it as an exceedingly prosperous occasion. We had significant success in conveying many key signals to the #scientific #community of drug design based on the insights gained from the Ligate Project. Several examples of which include: a. The progress of High-Performance Computing (#HPC) enables the feasibility of conducting Large-scale #Molecular #Dynamics simulations. A total of 16,442 molecular dynamics simulations have been performed for the BAP workflow, while the PS workflow has already completed over 8 million simulations, each lasting 100 picoseconds. b. It is feasible to get extensive and accurate binding free energy data on a big scale to build an AI Engines. c. One of the advantages of Ligate Project is the ability to apply freshly created models to these trajectories in order to extract information and validate multiple models. We express our gratitude to the organizing committee for hosting a scientifically rigorous workshop including enlightening presentations by distinguished #scientists. This event provided us with the opportunity to establish new connections and initiate potential partnerships for the future. It was a pleasure working with the administrative personnel on both sides.

Breakthroughs in Drug Discovery 👨🔬 👩🔬 Did you know? Drug discovery is a complex process that can take over a decade from initial research to market approval. Scientists use cutting-edge techniques like high-throughput screening and computer-aided drug design to identify promising compounds that can treat various diseases. It’s a meticulous journey from lab to pharmacy! #BRAINING European Commission, Jagiellonian University, Hospital del Mar Research Institute, Faculdade de Medicina da Universidade de Lisboa, University of Salamanca (Universidad de Salamanca)

During the EBVS GA in Cluj-Napoca, Romania, we dedicated a session to presenting the I-RESTART project to the EBVS Board and everyone interested in participating online. The session was chaired by members of the EBVS Executive Committee: Zoe Polizopoulou, Gonçalo Da Graça Pereira, Raphaël Guatteo, along with EBVS CEO Julie Rosser and EBVS Director of Education Mark Bowen. The main outcome of the project from the EBVS is the production of content on the topics identified as the most relevant for the EBVS members: 🔹 #DataLiteracy and clinical #statistics, including #BigData and #AI 🔹 skills for #business, including #CommunicationSkills 🔹 responsible medicines and chemical use, including #AntimicrobialResistance, use of #biocides, and their alternatives. Follow us for more information on the project in the future! https://buff.ly/3T2LIQX